Bifogade filer
Q3 Report 2024 Oncopeptides AB
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Stockholm – November 7, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2024.
“In the third quarter, a promising start in Spain was offset by slower-than-expected growth in Germany due to a soft market and a slow-down in Greece, resulting in a mixed third quarter for Oncopeptides,” said Sofia Heigis, CEO of Oncopeptides. “To ensure growth in the short term with prudent cost management, we are increasing our focus on the three largest markets Germany, Italy and Spain.”
Financial overview July-September
- Net sales amounted to SEK 8.5 M (2.8)
- Operating profit amounted to SEK -61.3 M (-37.3)
- Net profit amounted to SEK -60.2 M (-40.5)
- Earnings per share, before and after dilution, amounted to SEK -1.16 (-0.45)
- Cash balances at the end of the period amounted to SEK 250.0 M (233.6)
Significant events July-September
- Oncopeptides announces that the first patient has entered a new study evaluating the efficacy and safety of Pepaxti in German patients.
- Oncopeptides announces that it has signed an exclusive license and supply agreement with SCBIO Inc., a Korean pharmaceutical company for the commercialization of Pepaxti in South Korea.
Events after the period
- No significant events have occurred after the end of the period other than as mentioned in the report.
Financial overview of the group
| (SEK thousand) | 2024 Jul-Sep | 2023 Jul-Sep | 2024 Jan-Sep | 2023 Jan-Sep | 2023 Jan-Dec |
| Net sales | 8 507 | 2 805 | 21 734 | 29 883 | 35 220 |
| Whereof reversal of returns reserve USA | - | 229 | - | 24 274 | 24 330 |
| Operating profit | -61 251 | -37 297 | -200 164 | -172 467 | -253 447 |
| Profit after tax | -60 233 | -40 543 | -201 181 | -167 900 | -249 111 |
| Earnings per share, before and after dilution (SEK) | -1.16 | -0.45 | -1.33 | -1.86 | -2.76 |
| Cash flow from operating activities | -130 484 | -57 793 | -189 072 | -224 098 | -279 493 |
| Cash at the end of the period | 250 013 | 233 595 | 250 013 | 233 595 | 173 407 |
Conference call for investors, analysts and the media
Investors, financial analysts, and media are invited to participate in a webcast and a subsequent Q&A session, at 10:00 CET today.
The presentation will be hosted by Sofia Heigis, CEO, together with Henrik Bergentoft, CFO. The webcast will be held in English and published on the website of Oncopeptides – www.oncopeptides.com/en – in conjunction with the start of the presentation.
Information for participants
If you wish to participate via webcast, please use the link below.
https://ir.financialhearings.com/oncopeptides-q3-report-2024
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=50048827
CEO statement
In the third quarter, a promising start in Spain was offset by slower-than-expected growth in Germany due to a soft market and a slow-down in Greece, resulting in a mixed third quarter for Oncopeptides. To ensure growth in the short term with prudent cost management, we are increasing our focus on the three largest markets Germany, Italy and Spain.
Sales in Q3 2024 were SEK 8.5 million, compared to SEK 2.8 million in Q3 2023. Excluding a SEK 1.1 million down payment from the South Korean license deal, European sales in Q3 were slightly lower than in Q2, which in turn showed a 60 percent increase over Q1, illustrating volatility in an early-stage launch.
Germany remains our most important European market and accelerating sales there is our highest priority. According to our market intelligence, the German market for newly introduced late-stage multiple myeloma drugs has been generally slow during the third quarter. So far, during Q4 we have seen signs that the market in Germany is recovering.
The strong initial interest we saw in Spain in Q2 has started to transform into sales. The swift uptake follows the solid clinical experience from Pepaxti in the country. Since Pepaxti first became available in the country until today, about 80 percent of Spanish regions have already been activated, a strong start paving the way for continued sales growth during the end of 2024 and beyond. We also remain on track to secure market access in Italy, the European market with the second largest potential for Oncopeptides.
Outside of Europe, during the third quarter, we signed an exclusive licensing and supply agreement with South Korean pharma company SCBIO to commercialize Pepaxti, driven by demand from South Korean KOLs. We have now received a first milestone payment, the first ever for Oncopeptides and a testament to our ambition to build sales outside of Europe. It also illustrates Pepaxti’s ability to address a significant global unmet medical need in late-stage multiple myeloma.
We are fully committed to and focused on flawless execution on our European launch of Pepaxti, the core of our value creation. Following the slower than expected sales development in Q3, Oncopeptides continues to act by implementing an even stronger focus on our three largest markets and reducing our cost base elsewhere, without impairing our ability to market and sell Pepaxti in countries where we see near-term revenue potential. We continue to see great value in our pipeline and have invested in key activities ensuring progress.
The management team and I believe that a strong momentum in Spain, positive progress in Italy and the positive clinical experience that is being built in Germany together with increased cost-consciousness will be key to ensuring Oncopeptides’ success.
November 7, 2024
Sofia Heigis, CEO